dc.contributor.author | Heidari Majd, M | |
dc.contributor.author | Akbarzadeh, A | |
dc.contributor.author | Sargazi, A | |
dc.date.accessioned | 2018-08-26T08:54:31Z | |
dc.date.available | 2018-08-26T08:54:31Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54152 | |
dc.description.abstract | Hydrophobic drugs can absorb as guest molecules inside the cavity of cyclodextrins as host sites. So, forming the drug-cyclodextrin complex can exert a profound effect on the physicochemical and biological properties of the drugs. According to these advantages, in this study, we synthesized the tamoxifen (TMX) loaded cyclodextrin (CD)-conjugated MNPs to evaluate simultaneously the cytotoxicity and sustained release as well as hepatoprotective effect of this nanomedicine. The average size of Fe3O4-DPA-PEG-CD-TMX NPs was approximately 31 nm. By energy-dispersive X-ray spectroscopy (EDS), it was revealed that Fe3O4 constitutes 14.34% of the composition of modified MNPs. In the other words, nearly 85% of Fe3O4-DPA-PEG-CD NPs are made of dopamine (DPA), polyethylene glycol (PEG) and ?-cyclodextrin (?-CD). The TMX loaded MNPs (with entrapment efficiency of 33 mg TMX per unit CD (mg) and loading efficiency of 87.5%) showed sustained liberation of TMX molecules (with 91% release in 120 h). Cytotoxicity assay and apoptosis assay by TUNEL analysis revealed that the engineered Fe3O4-DPA-PEG-CD-TMX NPs were able to significantly inhibit the MCF-7 breast cancer cells. According to effect of CD on TMX sustained release, it was found that CD can decrease the hepatotoxicity induced by TMX nearly 30%. Based upon these findings, we suggest the Fe3O4-DPA-PEG-CD-TMX NPs as an effective multifunctional nanomedicine with simultaneous therapeutic and hepatoprotective effects. é 2016 Informa UK Limited, trading as Taylor & Francis Group. | |
dc.language.iso | English | |
dc.relation.ispartof | Artificial Cells, Nanomedicine and Biotechnology | |
dc.subject | Biomaterials | |
dc.subject | Cell death | |
dc.subject | Cyclodextrins | |
dc.subject | Drug delivery | |
dc.subject | Energy dispersive spectroscopy | |
dc.subject | Medical nanotechnology | |
dc.subject | Molecules | |
dc.subject | Nanomagnetics | |
dc.subject | Nanoparticles | |
dc.subject | X ray spectroscopy | |
dc.subject | Biological properties | |
dc.subject | Cyclodextrin complexes | |
dc.subject | Energy dispersive X ray spectroscopy | |
dc.subject | Entrapment efficiency | |
dc.subject | Hepatoprotective effects | |
dc.subject | Magnetic nano-particles | |
dc.subject | MCF-7 breast cancer cells | |
dc.subject | Tamoxifen | |
dc.subject | Iron compounds | |
dc.subject | beta cyclodextrin | |
dc.subject | cyclodextrin | |
dc.subject | dopamine | |
dc.subject | macrogol | |
dc.subject | magnetic nanoparticle | |
dc.subject | tamoxifen | |
dc.subject | antineoplastic agent | |
dc.subject | beta cyclodextrin derivative | |
dc.subject | drug carrier | |
dc.subject | macrogol derivative | |
dc.subject | magnetite | |
dc.subject | magnetite nanoparticle | |
dc.subject | tamoxifen | |
dc.subject | animal cell | |
dc.subject | apoptosis assay | |
dc.subject | Article | |
dc.subject | cancer inhibition | |
dc.subject | controlled study | |
dc.subject | drug cytotoxicity | |
dc.subject | drug delivery system | |
dc.subject | energy dispersive X ray spectroscopy | |
dc.subject | liver cell | |
dc.subject | liver protection | |
dc.subject | liver toxicity | |
dc.subject | MCF-7 cell line | |
dc.subject | nonhuman | |
dc.subject | particle size | |
dc.subject | rat | |
dc.subject | sustained drug release | |
dc.subject | TUNEL assay | |
dc.subject | animal | |
dc.subject | apoptosis | |
dc.subject | cell survival | |
dc.subject | chemistry | |
dc.subject | cytology | |
dc.subject | dose response | |
dc.subject | drug effects | |
dc.subject | drug formulation | |
dc.subject | drug release | |
dc.subject | female | |
dc.subject | human | |
dc.subject | kinetics | |
dc.subject | physiology | |
dc.subject | primary cell culture | |
dc.subject | procedures | |
dc.subject | transport at the cellular level | |
dc.subject | ultrastructure | |
dc.subject | Animals | |
dc.subject | Antineoplastic Agents | |
dc.subject | Apoptosis | |
dc.subject | beta-Cyclodextrins | |
dc.subject | Biological Transport | |
dc.subject | Cell Survival | |
dc.subject | Dopamine | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Drug Carriers | |
dc.subject | Drug Compounding | |
dc.subject | Drug Liberation | |
dc.subject | Female | |
dc.subject | Ferrosoferric Oxide | |
dc.subject | Hepatocytes | |
dc.subject | Humans | |
dc.subject | Kinetics | |
dc.subject | Magnetite Nanoparticles | |
dc.subject | MCF-7 Cells | |
dc.subject | Particle Size | |
dc.subject | Polyethylene Glycols | |
dc.subject | Primary Cell Culture | |
dc.subject | Rats | |
dc.subject | Tamoxifen | |
dc.title | Evaluation of host-guest system to enhance the tamoxifen efficiency | |
dc.type | Article | |
dc.citation.volume | 45 | |
dc.citation.issue | 3 | |
dc.citation.spage | 441 | |
dc.citation.epage | 447 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.3109/21691401.2016.1160916 | |